Trial · NCT01586624
Results by group128
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 128
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 1 (Steady State Dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib) | Total SAEs | 10 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 2 (Steady State Dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib) | Total SAEs | 11 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 3 (Steady State Dose of 100 mg OD Vandetanib + 75 mg BD Selumetinib) | Total SAEs | 13 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 4 (Steady State Dose of 100 mg OD Vandetanib + 100 mg OD Selumetinib) | Total SAEs | 5 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 5a (Steady State Dose of 100 mg OD Vandetanib + 125 mg OD Selumetinib) | Total SAEs | 28 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 5b (Steady State Dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib) | Total SAEs | 10 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 6 (Steady State Dose of 300 mg OD Vandetanib + 50 mg BD Selumetinib) | Total SAEs | 14 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Expansion Phase (Steady State Dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib) | Total SAEs | 14 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 1 (Steady State Dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib) | Total NSAEs | 99 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 2 (Steady State Dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib) | Total NSAEs | 90 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 3 (Steady State Dose of 100 mg OD Vandetanib + 75 mg BD Selumetinib) | Total NSAEs | 70 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 4 (Steady State Dose of 100 mg OD Vandetanib + 100 mg OD Selumetinib) | Total NSAEs | 94 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 5a (Steady State Dose of 100 mg OD Vandetanib + 125 mg OD Selumetinib) | Total NSAEs | 161 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 5b (Steady State Dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib) | Total NSAEs | 98 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 6 (Steady State Dose of 300 mg OD Vandetanib + 50 mg BD Selumetinib) | Total NSAEs | 114 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Expansion Phase (Steady State Dose of 200 mg OD Vandetanib + 50 mg BD Selumetinib) | Total NSAEs | 130 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 1 (Steady State Dose of 100 mg OD Vandetanib + 25 mg BD Selumetinib) | Total treatment emergent AEs | 107 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 2 (Steady State Dose of 100 mg OD Vandetanib + 50 mg BD Selumetinib) | Total treatment emergent AEs | 99 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 3 (Steady State Dose of 100 mg OD Vandetanib + 75 mg BD Selumetinib) | Total treatment emergent AEs | 79 | Adverse events | |
| Number of Serious Adverse Events, Non-serious Adverse Events and Treatment Emergent Adverse Events. | Dose Escalation Phase Cohort 4 (Steady State Dose of 100 mg OD Vandetanib + 100 mg OD Selumetinib) | Total treatment emergent AEs | 93 | Adverse events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01586624/results